Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Raises $10M, Targeting $20.5M

NEW YORK (GenomeWeb News) – Foundation Medicine has raised $10 million toward a $20.5 million financing round, the company disclosed in a regulatory filing with the US Securities and Exchange Commission on Tuesday.

A company spokesman declined to comment on the filing or provide information on investors in the round. According to the SEC document, one investor has participated in the equity round so far.

Foundation Medicine CEO Michael Pellini told GenomeWeb Daily News sister publication Clinical Sequencing News in June that the firm intends to obtain CLIA certification for its sequencing-based cancer test this year and to launch it as a laboratory-developed test in the second quarter of 2012.

The Cambridge, Mass.-based pharmacogenomics company previously raised $25 million in a Series A round last year. Since the start of the year, it has inked two deals, one with Novartis and the other with Celgene, for use of its genomic tests in clinical trials.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.